Milestone Pharmaceuticals (NASDAQ:MIST) Price Target Lowered to $7.00 at Wells Fargo & Company

Posted by Stanley Muller on May 14th, 2026

Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) had its price target cut by equities research analysts at Wells Fargo & Company from $8.00 to $7.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target suggests a potential upside of 338.87% from the stock’s previous close.

MIST has been the subject of a number of other reports. Raymond James Financial assumed coverage on Milestone Pharmaceuticals in a research note on Friday, April 10th. They issued a “strong-buy” rating and a $6.00 target price for the company. Zacks Research cut shares of Milestone Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 24th. Finally, Wall Street Zen raised shares of Milestone Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Milestone Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $7.25.

Read Our Latest Stock Report on MIST

Milestone Pharmaceuticals Price Performance

Shares of Milestone Pharmaceuticals stock traded down $0.13 on Thursday, hitting $1.60. 1,126,024 shares of the company were exchanged, compared to its average volume of 2,228,470. The stock has a market capitalization of $190.83 million, a price-to-earnings ratio of -2.02 and a beta of 1.04. The company has a 50-day moving average price of $1.70 and a 200 day moving average price of $1.93. Milestone Pharmaceuticals has a 1-year low of $1.00 and a 1-year high of $3.06. The company has a quick ratio of 7.96, a current ratio of 8.01 and a debt-to-equity ratio of 1.37.

Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.17). The company had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $30.12 million. As a group, sell-side analysts predict that Milestone Pharmaceuticals will post -0.47 earnings per share for the current fiscal year.

Insider Buying and Selling at Milestone Pharmaceuticals

In other Milestone Pharmaceuticals news, CEO Joseph Oliveto sold 36,500 shares of the stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $2.26, for a total transaction of $82,490.00. Following the completion of the transaction, the chief executive officer owned 446,244 shares of the company’s stock, valued at $1,008,511.44. This trade represents a 7.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 19.50% of the company’s stock.

Institutional Trading of Milestone Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in MIST. Propel Bio Management LLC increased its holdings in Milestone Pharmaceuticals by 186.1% in the 3rd quarter. Propel Bio Management LLC now owns 5,124,890 shares of the company’s stock valued at $10,250,000 after purchasing an additional 3,333,333 shares during the last quarter. Orbimed Advisors LLC acquired a new position in Milestone Pharmaceuticals during the third quarter worth $6,444,000. Marshall Wace LLP boosted its position in shares of Milestone Pharmaceuticals by 289.8% during the fourth quarter. Marshall Wace LLP now owns 1,656,821 shares of the company’s stock worth $3,347,000 after buying an additional 1,231,793 shares during the period. Pathstone Holdings LLC acquired a new stake in shares of Milestone Pharmaceuticals in the third quarter valued at $2,000,000. Finally, Boxer Capital Management LLC acquired a new stake in shares of Milestone Pharmaceuticals in the third quarter valued at $1,333,000. Institutional investors and hedge funds own 86.18% of the company’s stock.

Key Headlines Impacting Milestone Pharmaceuticals

Here are the key news stories impacting Milestone Pharmaceuticals this week:

Positive Sentiment: Milestone said CARDAMYST launch momentum is building, with about 600 prescriptions filled, roughly 400 unique prescribers, and national formulary coverage from Express Scripts, which could support future sales growth. Article Title
Positive Sentiment: The company also reported a strong cash position of $184.2 million, which it says should fund operations into the second half of 2027 and reduce near-term financing risk. Article Title
Neutral Sentiment: Management will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, giving investors another update opportunity, but the event itself is unlikely to materially change fundamentals. Article Title
Negative Sentiment: Q1 EPS of -$0.20 missed estimates, and revenue of $0.24 million fell far short of expectations, reinforcing concerns that CARDAMYST sales are still very early and not yet meaningful. Article Title
Negative Sentiment: Commercial spending rose sharply as the company pushed the CARDAMYST launch, which may worry investors about profitability until revenue scales more quickly. Article Title

Milestone Pharmaceuticals Company Profile

(Get Free Report)

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.